Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.

Celestia S. Higano, Lauren C. Harshman, Sabina Dizdarevic, John Logue, Timothy Richardson, Saby George, Danny Song, Igle J. de Jong, Jeffrey Tomaszewski, Fred Saad, Kurt Miller, Jeffrey Meltzer, Per Sandstrom, Bertrand F. Tombal, A. Oliver Sartor

    Research output: Contribution to journalMeeting AbstractAcademic

    Original languageEnglish
    Number of pages3
    JournalJournal of Clinical Oncology
    Issue number15
    Publication statusPublished - 20-May-2020

    Cite this